In 2010, Taiwan-based SHL launched Molly, an intuitive auto-injector featuring an ultra-compact design, simplified two-step operation and a permanently hidden needle. Molly is claimed to be the market's first pre-configured auto-injector.

In 2011, South Korea's Pohang University of Science and Technology developed a new drug delivery device for pulsatile and on-demand drug release based on electrically actuatable nanoporous membranes made of polypyrrole. Developed by Prof Jin Kon Kim, the device can be manipulated by a remote control while being planted inside a human body. The device can be combined with microchips and sensors, making it possible to program drug release in advance or detect the body's reaction to a drug injection. Experts are anticipating this achievement to be applied to many kinds of hormone therapies for conditions such as infertility, dwarfism, osteoporosis and diabetes, as well as chronic diseases such as insomnia, angina pectoris, asthma and pain control, all of which require discontinuous and prompt drug delivery.

Researchers at National University of Singapore are doing research on 3D patient-specific chemotherapeutic drug delivery to brain tumors and are developing a computer-assisted model of a commercial drug delivery implant system.

In 2011, India's Panacea Biotec developed Albumin bound Paclitaxel particles formulation, PacliALL. A cost-effective and novel drug delivery product, PacliALL offers the advantage of improved safety over conventional formulations of Paclitaxel and is meant to be used as a chemotherapeutic agent for the treatment of breast cancer.